ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Behcet’s syndrome"

  • Abstract Number: 3035 • 2015 ACR/ARHP Annual Meeting

    HLA B51 and Possible Associated Autoimmune Disorders Other Than Behcets Disease: A Retrospective Cohort Study

    Luis Salayandia1, Wilmer Sibbitt Jr.1, Arthur Bankhurst2, Roderick Fields3, Gladys Cook4, Konstantin Konstantinov5 and Suzanne Emil1, 1Rheumatology, University of New Mexico, Albuquerque, NM, 2Rheum/ MSC 105550, University of NM Med Ctr, Albuquerque, NM, 3Rheumatology, University of New Mexico, Albquerque, NM, 4Rheumatology, UNM, Albuquerque, NM, 51 University Of New Mexico, University of New Mexico, Albuquerque, NM

    Background/Purpose:  The diagnostic utility of HLA B51 in association with Behcet’s disease has been clearly identified; however the correlation of HLA B51 with other autoimmune…
  • Abstract Number: 3225 • 2015 ACR/ARHP Annual Meeting

    Whole Exome Sequencing Identifies Rare Protein-Coding Variants in Behcet’s Disease

    Mikhail Ognenovski1, Paul Renauer1, Ina Koetter2, Joerg C. Henes3, Bruno Casali4, Carlo Salvarani5, Haner Direskeneli6, Kenneth M. Kaufman7 and Amr H. Sawalha1, 1Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2Internal Medicine IV Rheumatology, Asklepios Klinik Altona, Hamburg, Germany, 3Department of Internal Medicine II, Rheumatology Division, University Hospital Tuebingen, Tuebingen, Germany, 4Divisione di Biologia Molecolare, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy, 5Rheumatology, Arcispedale S.Maria Nuova, Reggio Emilia, Italy, 6Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, 7Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Behcet’s disease (BD) is a systemic inflammatory disease characterized by recurrent oral and genital ulcers, skin lesions, uveitis, and other organ complications such as…
  • Abstract Number: 3036 • 2015 ACR/ARHP Annual Meeting

    The Association Between Behcet’s Disease, Myelodysplastic Syndrome and Trisomy 8

    Won-Seok Lee1, Yun Jung Choi2, Myong-Joo Hong3, Chang-Hoon Lee4, Myeung Su Lee5, Young Sun Suh6, Sang-Il Lee7, Yong Gon Cho8 and Wan-Hee Yoo9, 1Division of Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine of Chonbuk National University Hospital-Chonbuk National University, jeonju, South Korea, 2Division of Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine of Chonbuk National University Hospital-Chonbuk National University, JeonJu, South Korea, 3Internal Medicine, Presbyterian Medical center, Jeonju, South Korea, 4Department of Internal Medicine, School of Medicine, Wonkwang University, Iksan, Chonbuk, South Korea, 5Internal Medicine, School of Medicine, Wonkwang University, Iksan, Chonbuk, South Korea, 6Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea, 7Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, South Korea, 8Department of Laboratory medicine, Chonbuk National University Medical School and Hospital, Jeonju, South Korea, 9Division of Rhuematology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine of Chonbuk National University Hospital-Chonbuk National University, Jeonju, South Korea

    Background/Purpose: Behcet’s disease (BD) is a systemic vasculitis, whereas myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematologic disorders characterized by ineffective hematopoiesis. Some…
  • Abstract Number: 3226 • 2015 ACR/ARHP Annual Meeting

    Increased Serum Levels of IgG Antibodies Against to Alpha-Enolase Are Associated with Severity of Oral Ulcers in Patients with Behcet’s Disease

    Shin Eui Kang1, Sang Jin Lee2,3, Jin Kyun Park2,4, Joo Youn Lee2, Eun Young Lee3, Eun Bong Lee3 and Yeong Wook Song3,5, 1Department of Molecular Medicine and Biopharmaceutical Sciences, BK 21 plus Graduate School of Convergence Science and Technology, and College of Medicine or College of Parmarcy, Seoul National University, Seoul, South Korea, 2Department of Molecular Medicine and Biopharmaceutical Sciences, BK21 plus Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy, Seoul National University, Seoul, South Korea, 3Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, 4Department of Molecular Medicine and Biopharmaceutical Sciences Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy Seoul National University, Seoul, South Korea, 5Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine Seoul National University, Seoul, South Korea

    Background/Purpose: Behcet's Disease (BD) is a chronic inflammatory disease characterized by recurrent oral and genital ulcers, skin lesions, uveitis, and arthritis. Although the etiology of…
  • Abstract Number: 3037 • 2015 ACR/ARHP Annual Meeting

    Serum Anti-Lysozyme Is Associated with Disease Activity of Behcet’s Disease

    Jin Su Park1, Mi-il Kang2, You Jung Ha3, Yong-Beom Park4, Soo-Kon Lee5 and Sang-Won Lee6, 1Department of Internal Medicine, NHIS Ilsan Hospital, Goyang-si Gyeounggi-do, South Korea, 2Department of Internal Medicine, Dankook University Hospital, Cheonan-si Chungcheongnam-do, South Korea, 3Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea, 4Yonsei University College of Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul, South Korea, 5Internal Medicine, Yonsei Univ College of Med, Seoul, South Korea, 6Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea

    Background/Purpose: To investigate the association between autoantibodies against non- myeloperoxidase (MPO) neutrophil granule antigens and activity of Behcet’s disease (BD). Methods: We consecutively enrolled 51…
  • Abstract Number: 3038 • 2015 ACR/ARHP Annual Meeting

    Serum CXCL8, 10 and 12 Are Increased in Patients with Behcet’s Disease and CXCL10 Levels Are Correlated with Number of Erythema Nodosum

    Sang Jin Lee1,2, Hyun Jung Yoo3, Hyun Mi Kwon4, Jin Young Moon4, Jin Kyun Park5, Eun Young Lee5, Eun Bong Lee4 and Yeong Wook Song5, 1Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, 2Department of Molecular Medicine and Biopharmaceutical Sciences, BK21 plus Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy, Seoul National University, Seoul, South Korea, 3Department of Molecular Medicine and Biopharmaceutical Sciences, BK 21 plus Graduate School of Convergence Science and Technology, and College of Medicine or College of Parmarcy, Seoul National University, Seoul, South Korea, 4Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, 5Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea

    Background/Purpose: Chemokines are multifunctional mediators that control leukocyte recruitment into the inflammatory sites and enhance immune responses. It remains to be investigated which chemokines are…
  • Abstract Number: 3039 • 2015 ACR/ARHP Annual Meeting

    Possible Contribution of HLA-A0207, B5201 and IL-23 Receptor Polymorphism in Ocular Behçet Disease

    Toshikatsu Kaburaki1, Shinji Harihara2, Rie Tanaka3, Hiromasa Sawamura4, Ai Nishi4, Atsushi Hatamochi5, Jun Shimizu6, Masumi Takeuchi7, Shoji Kuwata8, Hidetoshi Kawashima9 and Fujio Takeuchi10, 1Ophthalmology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, 2Division of Anthropology, Department of Biological Science, The University of Tokyo Graduate School of Science, Tokyo, Japan, 3Department of Ophtalmology, The University of Tokyo Graduate School of Medicine,, Tokyo, Japan, 4Department of Ophtalmology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, 5Department of Dermatology, Dokkyo Medical University, Tochigi, Japan, 6Department of Neurology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, 7Teikyo University Support Center for Women Physicians and Researchers, Teikyo University School of Medicine, Tokyo, Japan, 8Third Department of Internal Medicine, Teikyo University Chiba Medical Center, Teikyo University School of Medicine, Chiba, Japan, 9Department of Ophthalmology, Jichi Medical University, Tochigi, Japan, 10Department of Allergy and Rheumatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan

    Background/Purpose: Behçet's disease (BD) is known to be associated with HLA-B*51:01 and HLA- A*26:01 in many different ethnic groups. Recently, HLA-A*02:07, IL-10 and IL23R-IL12RB polymorphisms…
  • Abstract Number: 3040 • 2015 ACR/ARHP Annual Meeting

    Predictive Factors of Long-Term Clinical Outcome in Patients with Ocular Involvement Secondary to Behcet’s Syndrome

    Rosaria Talarico1, Michele Figus2, Anna d'Ascanio1, Rossella Neri1, Chiara Baldini1, Chiara Tani3 and Marta Mosca1, 1Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, 2Department of Surgical, Medical, Molecular Pathology and Emergency, University of Pisa, Pisa, Italy, 3University of Pisa, Pisa, Italy

    Background/Purpose: Behçet's syndrome (BS) is a multisystemic, chronic relapsing inflammatory disease classified among the vasculitis. Eye involvement represent one of the most serious manifestation of…
  • Abstract Number: 2853 • 2014 ACR/ARHP Annual Meeting

    Comparative Study of Infliximab Versus Adalimumab in Patients with Refractory Uveitis Due to Behçet´s Disease. Multicenter Study of 125 Cases

    Leyre Riancho-Zarrabeitia1, Vanesa Calvo-Río1, Ricardo Blanco1, Paz Rodríguez-Cundín2, Emma Beltrán3, Juan Sánchez Bursón Sr.4, Marina Mesquida5, Alfredo Adan5, M. Victoria Hernández6, Marisa Hernandez Grafella7, Elia Valls Pascual8, Lucía Martinez-Costa9, Agusti Sellas-Fernandez10, Miguel Cordero-Coma11, Manuel Díaz-Llopis12, Roberto Gallego12, Jose Luis García Serrano13, Norberto Ortego-Centeno14, Jose M Herreras15, Alejandro Fonollosa16, Angel M. Garcia-Aparicio17, Olga Maiz Alonso18, Ana Blanco19, Ignacio Torre Salaberri20, Cruz Fernández- Espartero21, Vega Jovani22, Diana Peiteado23, Esperanza Pato24, Juan Cruz25, Carlos Férnandez Cid26, Elena Aurrecoechea27, Miriam García-Arias28, Miguel Angel Caracuel-Ruiz29, Carlos Alberto Montilla Morales30, Antonio Atanes-Sandoval31, Félix Francisco32, Santos Insua33, Senen González-Suárez34, Maria Amalia Sanchez Andrade35, Fernando Gamero36, Luis Francisco Linares Ferrando37, Fredeswinda Romero38, A. Javier García-González39, Raquel Almodóvar González40, Enrique Minguez41, Carmen Carrasco Cubero42, Alejandro Olive43, Julio Vázquez44, Oscar Ruiz Moreno45, Fernando Jiménez-Zorzo45, Javier Manero45, Santiago MuÑoz Fernandez46, Javier Rueda-Gotor1, Trinitario Pina1, Montserrat Santos-Gómez1 and Miguel A. González-Gay1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 2Preventive Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 3Rheumatology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, 4Rheumatology. Hospital de Valme., Sevilla, Spain, 5Ophthalmology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 6Arthritis Unit, Department of Rheumatology, Hospital Clinic, Barcelona, Barcelona, Spain, 7Ophthalmology. Hospital General universitario de Valencia, Valencia, Spain, 8Rheumatology. Hospital Peset, Valencia, Spain, 9Ophthalmology. Hospital Peset, Valencia, Spain, 10H. Vall d'Hebron, Barcelona, Spain, 11Ophthalmology, Hospital de León. Spain, León, Spain, 12Ophthalmology, Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, 13Ophthalmology. Hospital San Cecilio, Granada, Spain, 14Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, 15Ophthalmology. Hospital Universitario, IOBA, Valladolid, Spain, 16Ophthalmology, Hospital de Cruces. Bilbao. Spain, Bilbao, Spain, 17Rheumatology, Virgen de la Salud Hospital, Toledo, Spain, 18Rheumatology, Hospital Universitario de Donostia. San Sebastián. Spain, San Sebastián, Spain, 19Ophthalmology. Hospital Donosti, San Sebastián, Spain, 20Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, 21Rheumatology, Hospital Universitario de Móstoles. Madrid. Spain, Madrid, Spain, 22Rheumatology. Hospital General de Alicante, Alicante, Spain, 23Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, 24Rheumatology. Hospital Clínico San Carlos, Madrid, Spain, 25Rheumatology. Hospital de Pontevedra, Pontevedra, Spain, 26Ophthalmology. Hospital de Pontevedra, Pontevedra, Spain, 27Hospital Sierrallana. Torrelavega, Torrelavega, Spain, 28Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 29Plaza Cruz Roja, 1, H. Reina Sofia, Cordoba, Spain, 30Hospital Clínico Universitario de Salamanca, Salamanca, Spain, 31Rheumatology Division. C. Hospitalario Universitario A Coruña, A Coruña, Spain, 32Rheumatology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, 33Rheumatology. Hospital Universitario Santiago de Compostela, A Coruña, Spain, 34Rheumatology. Hospital Cabueñes, Gijón, Spain, 35Hosp. Lucus Augusti, Lugo, Spain, 36Rheumatology. Hospital San Pedro Alcantara, Cáceres, Spain, 37Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, 38Rheumatology, Jiménez Díaz Foundation University Hospital, Madrid, Spain, 39Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, 40Rheumatology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain, 41Ophthalmology. Hospital Clínico de Zaragoza, Zaragoza, Spain, 42Rheumatology, Hospital de Merida, Mérida, Spain, 43Rheumatology Service, Germans Trias Pujol Hospital, Barcelona, Spain, 44Rheumatology. Hospital de Ferrol, A Coruña, Spain, 45Ophthalmology and Rheumatology. Hospital Miguel Servet Zaragoza, Spain, Zaragoza, Spain, 46Sección de Reumatología, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain

    Background/Purpose: To compare the efficacy of infliximab (IFX) versus adalimumab (ADA) as first biologic drug in refractory uveitis due to Behçet's disease (BD) for 1-year…
  • Abstract Number: 2753 • 2014 ACR/ARHP Annual Meeting

    Reduced Heart Rate Variability in Patients with Behcet’s Disease

    Joung-Wook Lee1, Seung-Geun Lee2, Eun-Kyoung Park2 and Geun-Tae Kim3, 1Divsion of Rheumatology, Department of Internal Medicine, Busan St. Marys center, Busan, South Korea, 2Divsion of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, South Korea, 3Division of Rheumatology, Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea

    Background/Purpose The autonomic nervous system, including the sympathetic and parasympathetic nervous systems, has an important role in the triggering of ventricular arrhythmias and sudden cardiac…
  • Abstract Number: 2854 • 2014 ACR/ARHP Annual Meeting

    Effect of Apremilast on Quality of Life and Physical Function in Patients with Behçet’s Syndrome

    Gulen Hatemi1, Melike Melikoglu1, Recep Tunc2, Cengiz Korkmaz3, Banu Turgut Ozturk4, Cem Mat5, Peter A. Merkel6, Kenneth Calamia7, Lilia Pineda8, Ziqi Liu8, Randall M. Stevens8, Hasan Yazici1 and Yusuf Yazici9, 1Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, 2Necmettin Erbakan University, Meram Medical Faculty,Division of Rheumatology, Konya, Turkey, 3EskiÅŸehir Osmangazi University, EskiÅŸehir, Turkey, 4Selçuk University, Konya, Turkey, 5Istanbul University, Cerrahpasa Medical Faculty, Dermatology, Istanbul, Turkey, 6Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 7Administration, Mayo Clinic Health System in Waycross, Waycross, GA, 8Celgene Corporation, Warren, NJ, 9Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY

    Background/Purpose:  The oral ulcers in Behçet’s syndrome (BS) can be painful, causing difficulty in eating and speaking, and can impair the quality of life. Apremilast…
  • Abstract Number: 2732 • 2014 ACR/ARHP Annual Meeting

    Massive Ex Vivo Expansion of Functionally Stable Behcet’s Patient-Derived Regulatory T Cell Clones

    Johannes Nowatzky1, Olivier Manches1, Yusuf Yazici2 and Juan Lafaille1, 1New York University School of Medicine, New York, NY, 2Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY

    Background/Purpose: Adoptive transfer of regulatory T cells (Treg) is a promising strategy for the treatment of human autoimmune diseases. Most currently tested approaches focus on…
  • Abstract Number: 2756 • 2014 ACR/ARHP Annual Meeting

    Treatment of Mucocutaneous Manifestations in Behçet’s Disease with Anakinra: A Pilot Open-Label Study

    Peter C. Grayson1, Yusuf Yazici2, Elaine Novakovich3, Elizabeth Joyal4, Raphaela T. Goldbach-Mansky4 and Cailin H. Sibley3,5, 1NIAMS Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD, 2Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 3National Institutes of Health Clinical Center, Bethesda, MD, 4NIAMS, National Institutes of Health Clinical Center, Bethesda, MD, 5Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR

    Background/Purpose: IL-1 blocking therapy shows promise in the treatment of Behçet’s eye disease, but its effect on mucocutaneous manifestations is unknown. Methods: 6 patients with…
  • Abstract Number: 2208 • 2014 ACR/ARHP Annual Meeting

    Ovarian Reserve Alterations in Premenopausal Women with Rheumatoid Arthritis, Behcet’s Disease and Spondyloarthritis – Impact on Anti-Muellerian Hormone Levels

    Joerg C. Henes1, Julia Froeschlin2, Andre Taran3, Theodoros Xenitidis4 and Melanie Henes5, 1Department of Internal Medicine II, Rheumatology Division, University Hospital Tuebingen, Tuebingen, Germany, 2University Tuebingen, Tuebingen, Germany, 3University Hospital for Women Tuebingen, Tuebingen, Germany, 4Internal Medincine II, devision for Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, 5University Hospital for Women, Tuebingen, Germany

    Background/Purpose: Recent publications showed a negative influence of systemic lupus erythematosus and antiphospholipid antibody syndrome on female ovarian reserve (OR). Other authors did not find…
  • Abstract Number: 2757 • 2014 ACR/ARHP Annual Meeting

    Efficacy and Safety of ANTI-TNF ALPHA in BEHÇET Disease: A International Multicenter Registry of 122 Patients

    Hélène Vallet1, Sophie Rivière2, Alban Deroux3, Guillaume Moulis4, Olga Addimanda5, Carlo Salvarani6, Marc Lambert7, Philip Bielfeld8, Pascal Sève9, Jean Sibilia10, Jean Baptiste Fraison11, Yoland Schoindre12, Isabelle Marie13, Laurent Perard14, Thomas Papo15, Damien Sène16, Gaelle Leroux17, Valerie Royant18, Antoinette Perlat19, Xavier Mariette20, Olivier Lidove21, Olivier Fain22, Claire De Moreuil23, Gilles Blaison24, Phuc LE Hoang25, Eric Hachulla26, Bertrand Wechsler27, Barham Bodaghi28, Patrice Cacoub29 and David Saadoun30, 1Internal medicine, DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, 2Internal Medicine, Lapeyronie, Montpellier, France, 3Internal Medicine, CHU Grenoble, Grenoble, France, 4Internal Medicine department, Toulouse, Toulouse, France, 5S.C. Reumatologia, Arcispedale Santa Maria Nuova, I.R.C.C.S., Reggio Emilia, Italy, 6Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, 7CHRU Lille, Lille, France, 8CHU de Dijon, Dijon, France, 9Internal medicine, CHU Lyon, Lyon, France, 10Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, 11Hôpital Jean Verdier, Bondy, France, 12DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, PARIS, France, 13CHU de Rouen, Rouen, France, 14Hospices civils de Lyon, Lyon, France, 15Hôpital Bichat, Paris, France, 16Hopital Lariboisière, service de Médecine Interne, Paris, France, 17Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, 18Chartres, Chartres, France, 19Internal medicine, CHU de Rennes, Rennes, France, 20rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France, 21Médecine interne, Hôpital Croix-Saint-Simon, PARIS, France, 22Hôpital Saint Antoine, DHU i2B, Service de Médecine Interne, paris, France, 23CHU, Brest, France, 24Internal medicine, CHR, Colmar, France, 25Ophtalmology, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié Salpétrière, Paris, France, 26Internal Medicine, National Scleroderma Centre, Lille CEDEX, France, 27Internal Medicine, DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, 28Ophtalmology, Hôpital de la Pitié Salpêtrière, Paris, France, 29Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, 30DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France

    Background/Purpose Behçet’s disease (BD) is a systemic large vessel vasculitis with recurrent genital and oral ulceration, uveitis, cardiovascular, joints, neurological or gut symptoms. Treatment of…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology